Evotec AG has achieved a milestone in its biomarker alliance with Roche. Roche will use a response prediction marker, identified using Evotec's Proteome Profiling platform, in an extended Phase I oncology trial.
This is the first milestone achieved under the collaboration and license agreement signed in 2011. Under the initial three-year term, Evotec and Roche conduct biomarker discovery and validation programs for patient stratification in targeted cancer therapy. Evotec is eligible for further success-based payments upon clinical companion diagnostics development.
Dr. Mario Polywka, chief operating officer of Evotec AG, said, "We are delighted with receiving this milestone and the first validation of our novel biomarker concept with Roche. I would like to thank everyone involved in the project to date for the fantastic science they have developed and for the hard work and determination to see it succeed in a clinical setting."